СУЧАСНІ АСПЕКТИ ТИПІВ ВАКЦИН ДЛЯ ЗАПОБІГАННЯ SARS COV2 ІНФЕКЦІЇ
DOI:
https://doi.org/10.30888/2663-5712.2021-08-03-003Ключові слова:
вакцина, COVID-19, превенция, защита, иммунопрофилактика.Анотація
Аннотация. Статья про короткий обзор современных доступных вакцин для профилактики SARS-Cov2 инфекции у людей обоих полов и разного возраста, взрослых преимущественно.Metrics
Посилання
Coronavirus Death Rate (COVID-19) - Worldometer [Internet]. Available from:
https://www.worldometers.info/coronavirus/coronavirus-death-rate/
Li F. (2016). Structure, Function, and Evolution of Coronavirus Spike Proteins. Annual Review of Virology, 3(1), 237-261. doi:10.1146/annurev-virology-110615-042301
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz. 2020 May 20;16(1):9–26.
Wan Y, Shang J, Graham R, Baric R, Li F. (2020) Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of Virology, 94(7). doi:10.1128/JVI.00127-20
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 16;181(2), 271-280. doi: 10.1016/j.cell.2020.02.052
Mason R. (2020) Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal, 55(4). doi: 10.1183/13993003.00607-2020
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. The New England journal of medicine. 382(13), 1199–1207. doi: 10.1056/NEJMoa2001316
Wang W, Tang J, Wei F. (2020) Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. Journal of Medical Virology, 92(4), 441–447. doi: 10.1002/jmv.25689
Carlos W, Dela Cruz C, Cao B, Pasnick S, Jamil S. (2020) Novel Wuhan (2019-nCoV) Coronavirus. American Journal of Respiratory and Critical Care Medicine, 201(4), 7–8. doi: 10.1164/rccm.2014P7
Rothan H, Byrareddy S. (2020) The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity, 109(102433). doi: 10.1016/j.jaut.2020.102433
Ganneru B, Jogdand H, Dharam V, Molugu N, Prasad S, Vellimudu S, et al. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152. BioRxiv (2020) published online Sept 9, 2020. doi: 10.1101/2020.09.09.285445
Yadav P, Ella R, Kumar S, Patil D, Mohandas S, et al. Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques. Research Square, published online Sept 10, 2020. doi: 10.21203/rs.3.rs-65715/v1
Mohandas S, Yadav P, Shete A, et al. Immunogenicity and protective efficacy of BBV152: a whole virion inactivated SARS CoV-2 vaccine in the Syrian hamster model. Research Square, published online Sept, 2020. doi: 10.21203/rs.3.rs-65715/v1
Ella R, Vadrevu K, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152. J MedRxiv. 2020. doi: 10.1101/2020.12.11.20210419
Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv. 2020 Dec 22, 2020.12.21.20248643. doi: 10.1101/2020.12.21.20248643
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2021 Автори
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
